Toxin Conjugate Therapy of Cancer-Reference-Cited by-同舟云学术

Toxin Conjugate Therapy of Cancer

Published:2005-12 Issue:6 Volume:32 Page:591-595
ISSN:0093-7754
Container-title:Seminars in Oncology
language:en
Short-container-title:Seminars in Oncology

Author:

Wong Lucas,Suh Dick Y.,Frankel Arthur E.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference37 articles.

1. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2;LeMaistre;Blood,1998

2. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma;Olsen;J Clin Oncol,2001

3. Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin’s lymphoma;Dang;J Clin Oncol,2004

4. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia;Frankel;Clin Cancer Res,2003

5. A phase II study of denileukin diftitox (ONTAK) in patients with fludarabine-refractory B-cell chronic lymphocytic leukemia;Lilly;Proc Am Soc Clin Oncol,2005

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD123-targeted therapy in acute myeloid leukemia;Expert Review of Hematology;2021-06-03

2. Elderberries: A Source of Ribosome-Inactivating Proteins with Lectin Activity;Molecules;2015-01-30

3. Efficient Targeting of Head and Neck Squamous Cell Carcinoma by Systemic Administration of a Dual uPA and MMP-Activated Engineered Anthrax Toxin;PLoS ONE;2011-05-31

4. Use of Ribosome-Inactivating Proteins from Sambucus for the Construction of Immunotoxins and Conjugates for Cancer Therapy;Toxins;2011-04-29

5. A novel recombinant immuno-tBid with a furin site effectively suppresses the growth of HER2-positive osteosarcoma cells in vitro;Oncology Reports;2011-02-01